



MINUTES OF MEETING- 13.02.2026

Research Advisory Committee

1. CALL TO ORDER

Prof. (Dr) Lajya Devi Goyal (Dean Research) called to order the meeting for discussion at 03:30 PM on 13.02.2026.

• The following members were present in the meeting:-

Prof. (Dr.) Lajya Devi Goyal, Prof. (Dr.) Anuradha Raj, Prof. (Dr.) Gurvinder Pal Singh, Prof. (Dr) Ajay Kumar, Dr. Sivanantham Karishnamoorthi, Dr. Shailendra Singh Rana

The following members did not attend the meeting:-

Dr. Altaf Mir, Prof. (Dr) Rakesh Kakkar,

2. AGENDA

Following research projects were discussed by RAC and sent the subsequent comments:

S. No.	PI	Title Of The Study	Comments
I.	Dr. Shivani Bansal (Dermatology)	To investigate the clinicopathological characteristics of cases of plasma cell cheilitis- Cross-sectional retrospective Study	<ul style="list-style-type: none"><li>• In form 2: Sponsor details checked as state/govt/national and mentioned as NA regarding sponsor details to be corrected appropriately.</li><li>• Aim to be separated.</li><li>• Objective to be separated.</li><li>• Method- Study population &amp; study sample to be reviewed.</li><li>• Data collection: Study type is retrospective mentioned as telephonic follow-up – Data collection prospectively occurs. Please clarify.</li><li>• Statistical analysis to be provided in detail with appropriate SPSS version.</li></ul>

S. No.	PI	Title Of The Study	Comments
			<ul style="list-style-type: none"> <li>• Reference- to be Vancouver style.</li> <li>• Conflicts in any to be cleared with co-investigators.</li> </ul> <ul style="list-style-type: none"> <li>• Attach necessary proformas in English/ Punjabi/Hindi as per Aims Bathinda format.</li> <li>• Modify aims and objectives.</li> <li>• Kindly review sample size.</li> <li>• Sample size calculation is recommended? If convenience sampling then mention estimated no. available during the study period.</li> <li>• Mention Institutional version- SPSS 29.</li> <li>• Standardize to Vancouver style pattern across all, proportionately more recent reference are recommended.</li> <li>• 1 &amp; 8 are common references.</li> <li>• Reference no. 5 &amp; 12 are same.</li> </ul>
2.	Dr. Jawahar Singh (Psychiatry)	Psychosocial Determinants of Paraquat Poisoning at a Tertiary Care Centre in North India: A Cross-Sectional Study	<ul style="list-style-type: none"> <li>• Explicitly state what new insights this study will generate (e.g., region-specific determinants) and how these differ from prior studies.</li> <li>• Patients assessed soon after poisoning may have impaired cognition, delirium, or emotional distress, which can affect the validity of responses. Specify a minimum stabilization period or objective clinical criteria (e.g., resolution of delirium) before psychiatric assessment.</li> </ul>

S. No.	PI	Title Of The Study	Comments
			<ul style="list-style-type: none"> <li>• Cultural validation status, who will administer the scales and their training.</li> <li>• Add a section on data confidentiality, including coding of data, secure storage, and restricted access.</li> </ul> <hr/> <ul style="list-style-type: none"> <li>• Duration of study to be included in the title</li> <li>• Signature of Co PI missing</li> <li>• Forwarding by HoD missing</li> <li>• References not as per the Vancouver style of referencing</li> <li>• References to be numbered</li> </ul>
3.	Dr. Sapna Marcus Bhatti (Radiation Oncology)	A randomized, double-blind, parallel-group study to compare pharmacokinetics of JBP898 (proposed nivolumab biosimilar) and US-licensed Opdivo in participants with resected stage IIB, IIC or III melanoma requiring adjuvant treatment with nivolumab	<ul style="list-style-type: none"> <li>• DGCI approval letter not attached.</li> </ul> <hr/> <ul style="list-style-type: none"> <li>• Mention research question, null hypothesis and alternative hypothesis</li> <li>• Kindly cite the method used to determine the sample size.</li> <li>• Dropout/correlation source, missing data and Cite, describe handling, specify statistics/software</li> <li>• Define acronyms; justify endpoints</li> </ul>
4.	Dr. Vikas Lakhanpal (Neurology)	Decoding mitochondria - Driven Cellular Ageing and Oxidative Stress among Parkinson's disease Patients.	<p><b>In Form 2</b></p> <ul style="list-style-type: none"> <li>• Sponsor information CUPB, but mentioned as Nil.</li> <li>• Budget details- CUPB financial aspects on study needed clarity.</li> <li>• Point No. 1- Type of study to be mentioned.</li> <li>• Point No. 1- single center mentioned but multicentric as involved 2 centers</li> <li>• Point No. 3- To be mentioned NA.</li> </ul>

S. No.	PI	Title Of The Study	Comments
			<ul style="list-style-type: none"> <li>• Point No. 7- Sub point (iv) &amp; (v) need justification.</li> <li>• Point No. 7(vii)- Use of organ/body fluids mentioned as yes in point 7(iii) but 7(vii) mentioned as No. All biological samples to be consider as infectious.</li> <li>• 8(ii) Regarding consent- Mentioned as Research Staff. Is there any provision of Research Staff in the study? (Mentioned as non- funded study).</li> <li>• In Form 2 point no. 9. Not Checked for any option.</li> <li>• In Form 2 point no. 11. Not Checked for any option.</li> <li>• In form 2 point no. 13. Not Checked for any option.</li> </ul> <p><b>Duration of the protocol</b></p> <ul style="list-style-type: none"> <li>• Kindly review the start of the protocol and end of the protocol.</li> <li>• <b>Sample Size:</b> Calculation to be provided with reference study on sample size calculation.</li> <li>• <b>Location:</b> Punjab and surrounding places. Please clarify is it community based study??</li> <li>• <b>Methodology:</b> Need detailed methodology with suitable reference.</li> <li>• Data collection, Stastical analysis, Ethical part missing.</li> <li>• Reference should be in Vancouver style.</li> </ul> <p><b>The following :</b> Annexure details are not clear and to be mentioned in methodology with justification for the study and its objectives.</p> <ul style="list-style-type: none"> <li>➤ Patient information form.</li> <li>➤ Audit -C.</li> </ul>

S. No.	PI	Title Of The Study	Comments
			<ul style="list-style-type: none"> <li>➤ Personal Details (UPDDs Scale).</li> <li>➤ Hoehh and Yahr Scaling.</li> <li>• Revised plagiarism report with suggested modifications.</li> <li>• IEC approval of collaborating institute to be attached.</li> </ul> <hr/> <ul style="list-style-type: none"> <li>• <b>In Methodology:</b> May add limitation, duration of study and GANTT Chart (timeline chart)</li> <li>• Data analysis and statistics are not mentioned- it can be included by using parameteric (T-test/ANOVA) or non-parametric test for group comparison. Multivariate regression for association. Adjust for confounders (age, smoking from page 30) SPSS29 may also be mentioned for analysis.</li> <li>• Old and only a few references are only used, may add more &amp; recent references.</li> <li>• If possible quantify (e.g. identify biomarkers with &gt;80% sensitivity)</li> <li>• Mention criteria for 300 sample size collection.</li> </ul>
5.	Dr. Navita Aggarwal (Anatomy)	Prospectives of Mentor and Mentee on Ongoing Mentorship Program at AIIMS Bathinda: A longitudinal Study.	<ul style="list-style-type: none"> <li>• Please clarify methodology in respect of questionnaire and performa to be filled by Mentor &amp; Mentees.</li> <li>• How will you address follow up of mentors and mentees.</li> <li>• Reference should be in Vancouver style.</li> <li>• Co-PI will be mentor also. How will you address this conflict of interest?</li> </ul>

S. No.	PI	Title Of The Study	Comments
			<ul style="list-style-type: none"> <li>• Is there any current mentor-mentee program for Post graduate Residents in AIIMS, Bathinda?</li> <li>• Observational type of study can also be added in the study type.</li> <li>• Sample size should be determined before the initiation of the study.</li> <li>• Is every mentor, included in the study will give the consent to fill the form, since it is going to take 15-20 minutes per session?</li> <li>• Will mentor volunteer to participate in Focused Group Discussion?</li> <li>• A preliminary framework for the study should be completed and later on further modifications can be done.</li> </ul>
6.	Dr. Saurabh Nayak (Nephrology)	Biomarkers for prediction and early diagnosis of Heart failure in Chronic Kidney Disease.	<ul style="list-style-type: none"> <li>• A Radiologist should also be a Co-PI as MRI is needed in the project.</li> </ul>
7.	Dr. Vaibhav Saini (ENT)	CLINICORADIOLOGICAL FEATURES AND BIOCHEMICAL PARAMETERS OF PATIENTS UNDERGOING PARATHYROID ADENOMA EXCISION AND THEIR INFLUENCE ON POST OPERATIVE OUTCOMES -A RETROSPECTIVE COHORT STUDY.	<ul style="list-style-type: none"> <li>• Modify title.</li> <li>• Mention sample size.</li> <li>• Aim may be revised.</li> <li>• <b>In Primary objective:</b> Specify outcomes. If possible make it more specific</li> <li>• <b>In Methodology:</b> It lacks details on sample size calculation, data quality assurance &amp; handling of co-founders.</li> <li>• <b>In Bias if any:</b> may add-blinding during extraction.</li> </ul>

S. No.	PI	Title Of The Study	Comments
			<ul style="list-style-type: none"> <li>• <b>In statistical analysis:</b> May add – multivariate analysis for co-founders (e.g. age, comorbidities)</li> </ul>
8.	Prof. (Dr.) Gitanjali (Biochemistry)	Determining Age-Specific Total and Free Prostate-Specific Antigen (PSA) Reference Ranges for Healthy North Indian Men: A Retrospective Study.	<ul style="list-style-type: none"> <li>• Kindly check if abbreviation terms can be used in title.</li> <li>• The rationale could be strengthened by stating how the standardized reference ranges would <b>change current clinical decision-making</b> at AIIMS Bathinda or similar North Indian centers. Cite the references that has been used for obtaining reference ranges in south indian and international population.</li> <li>• Kindly mention the full form of CaP in exclusion criteria.</li> <li>• A clearer definition of "healthy" (e.g., absence of known prostate disease, no recent urinary infection) can be added.</li> <li>• Expand exclusion criteria to reduce biological and clinical confounding.</li> <li>• Provide justification for PSA cutoffs range used for exclusion.</li> <li>• The term "HER" appears instead of "EHR" in one section, which may need correction for clarity.</li> </ul>
9.	Prof. (Dr) Gitanjali (Biochemistry)	Assesment of urinary biochemical analysis and its correlation with stone analysis in nephrolithiasis patients- An Observational study.	<ul style="list-style-type: none"> <li>• Modify title.</li> <li>• Use 'assess' or 'evaluate' for observational study instead of 'determine' where appropriate. Add comparison to controls, as it is a case controlled design.</li> <li>• Make necessary changes in objective.</li> </ul>


S. No.	PI	Title Of The Study	Comments
			<ul style="list-style-type: none"> <li>• Ensure alignment with methodology: The study uses phase contrast for urine and chemical for stones.</li> <li>• It is "prospective" study if enrolling new patients then mention explicitly state "Prospective observational case- control study" to clarify it's not retrospective.</li> <li>• Specify Statistical tests: e.g, Chi- Square for categorical (crystal types) t-test/ Mann-Whitney for continuous, Pearson/Spearman for correlations. Adjust for confounders (age, diet).</li> <li>• Reference no. 4 is incomplete.</li> <li>• At page no. 20 make necessary changes in lifestyle variables.</li> <li>• PIS sheet in Punjabi is not visible.</li> </ul>
10.	Dr. Lata Goyal (Dentistry)	Clinical, histopathological and immunohistochemical analysis of plasma cell gingivitis: A retrospective study	<ul style="list-style-type: none"> <li>• The plasma cell gingivitis proposal submitted as PI. Also, the investigator is a part (Co- PI) in another retrospective study (on Plasma cell cheilitis) submitted by another PI. Kindly clarify.</li> </ul>
11.	Dr. Rachna (Pharmacology)	Diagnostic Utility of Delta-like 1 Ligand Detection in Tuberculous Meningitis: A Prospective Observational Study.	<ul style="list-style-type: none"> <li>• Ok &amp; Approved</li> </ul>
12.	Dr. Jai Ranjan (Microbiology)	Decoding Carbapenem Resistant-Hypervirulent Klebsiella pneumoniae: Clinical and laboratory characterisation to develop an Artificial intelligence-based Clinical Decision Support system to predict outcomes.	<ul style="list-style-type: none"> <li>• Ok &amp; Approved</li> </ul>


S. No.	PI	Title Of The Study	Comments
13.	Dr. Shailendra Rana (Dentistry)	Craniofacial analysis using AI-generated synthetic CT and 3D Computational framework to reduce radiation exposure to the patient	<ul style="list-style-type: none"> <li>• Modify title.</li> </ul>
14.	Dr. Narinder Kaur Walia	A quasi-experimental study to examine the effectiveness of Short Video Demonstration on knowledge and Practice of Incentive Spirometry use among Surgical Patients at AIIMS Bathinda.	<p><b>Form 2:</b></p> <ul style="list-style-type: none"> <li>• Point No. 3- Device mentioned under clinical Trials.</li> <li>• Please clarify the type of Clinical trial and device details.</li> <li>• Brief description of proposal with maximum 500 words- Not available / Not attached.</li> <li>• 7(Viii) Proper disposal of material – mentioned No. Is the device used in study single use (or) reusable?</li> <li>• <b>Problem Statement:</b> Not addressing the problem.</li> <li>• <b>Aim</b> is not clear.</li> <li>• <b>Objective:</b> Multiple objective.</li> <li>• How to standardize short – video.</li> <li>• <b>Study Population:</b> Inclusion and Exclusion criteria.</li> <li>• Sample size calculation and sample size is missing.</li> <li>• <b>Measurement tools-</b> Not complete.</li> <li>• <b>Methodology:</b> Not sufficiently provided with supporting Annexure details.</li> <li>• <b>PICF:</b> Incomplete PI details.</li> <li>• Reference list missing in Vancouver style.</li> </ul>


Minutes of Meeting held on 13.02.2026 regarding the evaluation of PG Thesis

  
Prof. (Dr.) Lajja Devi Goyal  
(Dean Research)

  
Prof. (Dr.) Anandha Raj  
(Associate Dean Research)

  
Prof. (Dr.) Gurvinder Pal  
Singh

  
Prof. (Dr.) Ajay Kumar

  
Dr. Sivanantham  
Karishnamoorthi

  
Dr. Shailendra Singh Rana